YH, G., KD, G., PC, L., & SR, G. Benralizumab: Effectiveness in Patients with Uncontrolled Severe Eosinophilic Asthma at 6 and 12 Months at a Third-Level Care Hospital. Capacity for ICS-LABA Therapy Reduction. Dove Medical Press.
Chicago Style (17th ed.) CitationYH, González-Tuyub, González-Iñiguez KD, Lizarazo-Guiza PC, and García-García SR. Benralizumab: Effectiveness in Patients with Uncontrolled Severe Eosinophilic Asthma at 6 and 12 Months at a Third-Level Care Hospital. Capacity for ICS-LABA Therapy Reduction. Dove Medical Press.
MLA (9th ed.) CitationYH, González-Tuyub, et al. Benralizumab: Effectiveness in Patients with Uncontrolled Severe Eosinophilic Asthma at 6 and 12 Months at a Third-Level Care Hospital. Capacity for ICS-LABA Therapy Reduction. Dove Medical Press.